- Verge Genomics has announced a three-year collaboration with Eli Lilly And Co LLY to research and develop novel therapies to treat amyotrophic lateral sclerosis (ALS), a motor neuron disease.
- Under the terms of the three-year agreement, Verge will receive up to $25 million in upfront equity investment and potential near-term payments, with an additional milestone value of $694 million and potential downstream royalties.
- Verge will apply its all-in-human platform to discover and validate new targets for ALS. The all-in-human platform is based on a proprietary collection of patient brain transcriptomes across various neurodegenerative diseases.
- Verge will apply its human-based discovery capabilities to validate targets.
- Lilly will select up to four targets identified by Verge with plans to advance through clinical development and commercialization.
- Price Action: LLY shares are down 1.75% at $231.70 in the premarket session on the last check Thursday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
